Grants.govNational Institutes of Health

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)

Posted Dec 5, 2024·open

AGENCY

HHS-NIH11

PROGRAM

Discretionary

AMOUNT

Up to $1.5M

CLOSES

Jan 7, 2027

Apply on Grants.gov ↗More info from funder ↗

Description

The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO which utilizes an R61/R33 phased approach.

Eligibility

Native American tribal governments (Federally recognized); Small businesses; For profit organizations other than small businesses; Independent school districts; State governments; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; Special district governments; Public housing authorities/Indian housing authorities; Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal organizations (other than Federally recognized tribal governments); City or township governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education

Contact

National Institutes of Health

grantsinfo@nih.gov

301-402-2541

Additional details

Funding instrument: Grant
Cost sharing required: No
Archived: Feb 12, 2027

Opportunity number: PAR-25-025

Search this number on Grants.gov for the official listing.